Jan 28, 2021 8:00am EST NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics
Jan 11, 2021 6:00am EST NeuBase Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Dec 23, 2020 4:05pm EST NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020
Dec 16, 2020 6:30am EST NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1
Dec 02, 2020 8:00am EST NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
Nov 17, 2020 8:00am EST NeuBase Therapeutics Announces Addition of Eriks Rozners, Ph.D. and Randy Davis, MBA to Scientific Advisory Board
Nov 10, 2020 8:00am EST NeuBase Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17
Oct 26, 2020 8:15am EDT NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D., to Present "Manufacturing Heat-Seeking Missiles Against Misbehaving Genes" at Tribe Public's Event on October 28, 2020
Oct 13, 2020 8:00am EDT NeuBase Therapeutics Announces Addition of Peter Nielsen, Ph.D., Inventor of Peptide Nucleic Acid Technology, to Scientific Advisory Board